Ian.Cd
IAN.CD operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales and licensing agreements.
Business. IAN.CD operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales and licensing agreements.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
IAN.CD operates in the pharmaceuticals industry, focusing on drug development and commercialization, primarily generating revenue through product sales and licensing agreements.
IAN.CD's capital structure is highly leveraged, with total liabilities of $359.03 million and total equity of -$103.04 million, resulting in a debt-to-equity ratio of -1.88. The company's liquidity position is weak, as evidenced by a current ratio of 0.71, indicating that current assets are insufficient to cover current liabilities. Free cash flow is negative at -$44.83 million, and operating cash flow is only $3.15 million, suggesting limited ability to fund operations or reduce debt.
Profitability metrics are mixed. The company reported a gross profit of $65.70 million, but this was offset by an operating loss of $15.42 million and a net loss of $40.20 million. Return on equity is high at 39.02%, but this is misleading due to the negative equity base. Return on assets is negative at -15.71%, indicating poor asset utilization.
Revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's financial snapshot does not provide segment-specific revenue data, but the absence of geographic breakdown suggests potential concentration risk.
Growth trajectory is uncertain. The company reported revenue of $143.99 million in the latest period, but there is no historical data provided to assess year-over-year growth. Analyst estimates for the last actual revenue were $78.38 million, suggesting a significant increase in the most recent period.
Risk factors include liquidity constraints and a high debt load. The company has a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a key flag. No recent events or filings are disclosed in the provided data to suggest material changes in the company's risk profile.
Recent events and filings are not disclosed in the provided data, so no specific information is available on recent corporate actions or regulatory developments affecting the company.
- IAN.CD has a highly leveraged capital structure with a negative equity position.
- The company's profitability is weak, with a net loss of $40.20 million despite a gross profit of $65.70 million.
- Liquidity is constrained, with a current ratio of 0.71 and negative free cash flow.
- Revenue growth appears to have accelerated in the latest period, but historical context is limited.
- The company faces significant liquidity and debt management challenges.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- IAN.CD Market data — financials · 2026-05-28
- Ianthus Capital Holdings Inc Market data — analyst estimates · 2026-05-28